Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Exelixis (EXEL)

Exelixis names Brenda Hefti General Counsel, succeeding Jeffrey Hessekiel effective Nov. 7

Neutral Impact 2 of 5 leadership Written later

Exelixis said General Counsel Jeffrey Hessekiel will step down, with his role ending November 7, 2025, and that his decision did not stem from any disagreement with the company. Brenda Hefti, currently Senior Vice President of Intellectual Property and Licensing, will take over as General Counsel on the same date, reporting to CEO Michael Morrissey. The change is a leadership transition in a legal role; the filing gives no financial figures.

Key points

  • Jeffrey Hessekiel, Executive Vice President and General Counsel, notified the company on November 4, 2025 of his resignation; he ceases the role November 7, 2025
  • Brenda Hefti, Senior Vice President, IP & Licensing, is promoted to General Counsel effective November 7, 2025
  • Hefti joined Exelixis in 2013 as corporate counsel and has led IP & Licensing since 2020
  • The filing states Hessekiel's departure was not the result of any disagreement with the company

The filing

CompanyExelixis (EXEL)
Form8-K, current report
Filed with the SECNov 7, 2025, 4:07 PM ET
Accession number0000939767-25-000133

Items reported: 5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.